食管癌新辅助治疗参与保存器官的研究进展

doi:10.3760/cma.j.cn371439-20201111-00133

摘要/Abstract

摘要：

食管鳞状细胞癌是我国常见的恶性肿瘤类型之一。局部晚期食管鳞状细胞癌是一种复杂的异质性疾病,治疗方法不断发展。目前,放化疗及手术等多学科综合治疗为其主要手段。然而,由于食管所处的特殊解剖部位,手术切除对患者的生理功能影响较大。在不影响患者整体疗效的基础上,采用保存食管的非手术治疗方法,对于改善患者生命质量等具有重要的意义。新辅助治疗作为一种非侵入性肿瘤治疗手段,在保存食管的综合治疗中扮演重要角色。近年来,陆续有新辅助治疗参与保存食管的食管癌综合治疗策略的研究,对这些研究进展的认识将为食管癌的综合治疗提供参考价值。

关键词: 食管肿瘤, 新辅助治疗, 保存器官, 综合治疗

Abstract:

Esophageal squamous cell carcinoma is one of the most common cancer in China, and locally advanced stage remains a heterogeneous and complex disease. Its treatments are constantly evolving. To date, radiochemotherapy and surgery are involved in the comprehensive treatment of this disease. However, because of the specifical anatomical location of esophagus, its physiological function will be impaired after surgical resection. If similar survival is obtained in esophageal cancer, an organ preserving strategy without surgery is of great significance for improving the quality of life. As a non-invasive tumor treatment method, neoadjuvant therapy plays an important role in the comprehensive treatment of preserving the esophagus. Recently, there are studies investigating the role of organ preserving strategy in the comprehensive treatment of esophageal cancer with neoadjuvant therapy, and the recognition of these advances will provide reference value for the comprehensive treatment of esophageal cancer.

Key words: Esophageal neoplasms, Neoadjuvant therapy, Organ preservation, Comprehensive treatment

杜晨, 苏思雨, 王利革, 于桂萍. 食管癌新辅助治疗参与保存器官的研究进展[J]. 国际肿瘤学杂志, 2021, 48(11): 673-677.

Du Chen, Su Siyu, Wang Lige, Yu Guiping. Advances in neoadjuvant therapy of esophageal cancer involved in organ preservation[J]. Journal of International Oncology, 2021, 48(11): 673-677.

参考文献 35

[1]	Ozawa S, Koyanagi K, Ninomiya Y, et al. Postoperative complications of minimally invasive esophagectomy for esophageal cancer[J]. Ann Gastroenterol Surg, 2020, 4(2):126-134. DOI: 10.1002/ags3.12315. doi: 10.1002/ags3.12315 pmid: 32258977
[2]	Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—the university of texas md anderson cancer center experience[J]. Cancer, 2017, 123(21):4106-4113. DOI: 10.1002/cncr.30953. doi: 10.1002/cncr.30953
[3]	Fitzgerald RC. Organ-preserving approaches in oesophageal cancer[J]. Lancet Oncol, 2018, 19(7):858-859. DOI: 10.1016/S1470-2045(18)30291-2. doi: S1470-2045(18)30291-2 pmid: 29861117
[4]	Bourbonne V, Pradier O, Schick U, et al. Cancer of the oesophagus and lymph nodes management in the neoadjuvant or definitive radiochemotherapy setting[J]. Cancer Radiother, 2019, 23(6-7):682-687. DOI: 10.1016/j.canrad.2019.07.130. doi: 10.1016/j.canrad.2019.07.130
[5]	de Gouw D, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis[J]. J Thorac Oncol, 2019, 14(7):1156-1171. DOI: 10.1016/j.jtho.2019.04.004. doi: 10.1016/j.jtho.2019.04.004
[6]	van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI: 10.1056/NEJMoa1112088. doi: 10.1056/NEJMoa1112088
[7]	Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial[J]. JAMA Surg, 2021, 156(8):721-729. DOI: 10.1001/jamasurg.2021.2373. doi: 10.1001/jamasurg.2021.2373
[8]	Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J]. J Clin Oncol, 2005, 23(10):2310-2317. DOI: 10.1200/JCO.2005.00.034. doi: 10.1200/JCO.2005.00.034
[9]	Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer: final analysis of randomized controlled phase Ⅲ trial ffcd 9901[J]. J Clin Oncol, 2014, 32(23):2416-2422. DOI: 10.1200/JCO.2013.53.6532. doi: 10.1200/JCO.2013.53.6532
[10]	Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD010511. DOI: 10.1002/14651858.CD010511.pub2.
[11]	van Rossum PSN, van Hillegersberg R, Meijer GJ, et al. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa[J]. Ann Surg, 2015, 262(2):e83-e84. DOI: 10.1097/SLA.0000000000000671. doi: 10.1097/SLA.0000000000000671
[12]	Xi M, Yang Y, Zhang L, et al. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: impact of histology on recurrence patterns and outcomes[J]. Ann Surg, 2019, 269(4):663-670. DOI: 10.1097/SLA.0000000000002670. doi: 10.1097/SLA.0000000000002670
[13]	Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?[J]. J Clin Oncol, 2015, 33(33):3866-3873. DOI: 10.1200/JCO.2014.59.9092. doi: 10.1200/JCO.2014.59.9092
[14]	Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer[J]. J Clin Oncol, 2014, 32(30):3400-3405. DOI: 10.1200/JCO.2014.56.7156. doi: 10.1200/JCO.2014.56.7156
[15]	Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer[J]. Dis Esophagus, 2017, 30(12):1-8. DOI: 10.1093/dote/dox100. doi: 10.1093/dote/dox086 pmid: 28881884
[16]	Shapiro J, Wijnhoven BP, van Lanschot JJ. Reply to letter: "Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa"[J]. Ann Surg, 2015, 262(2):e84-e85. DOI: 10.1097/SLA.0000000000-000675. doi: 10.1097/SLA.0000000000000675
[17]	Vollenbrock SE, van Dieren JM, Voncken FEM, et al. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer[J]. Eur Radiol, 2020, 30(5):2425-2434. DOI: 10.1007/s00330-019-06605-x. doi: 10.1007/s00330-019-06605-x pmid: 31965258
[18]	Cremonesi M, Garibaldi C, Timmerman R, et al. Interim¹⁸F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review[J]. Radiother Oncol, 2017, 125(2):200-212. DOI: 10.1016/j.radonc.2017.09.022. doi: S0167-8140(17)32589-6 pmid: 29029833
[19]	Yang Z, He B, Zhuang X, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy[J]. J Radiat Res, 2019, 60(4):538-545. DOI: 10.1093/jrr/rrz027. doi: 10.1093/jrr/rrz027
[20]	Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (presano): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI: 10.1016/S1470-2045(18)30201-8. doi: S1470-2045(18)30201-8 pmid: 29861116
[21]	Qin Q, Xu H, Liu J, et al. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis[J]. Int J Surg, 2018, 59:11-18. DOI: 10.1016/j.ijsu.2018.09.013. doi: S1743-9191(18)31636-4 pmid: 30261331
[22]	Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer[J]. Ann Surg, 2014, 260(5):813-804; discussion 813-804. DOI: 10.1097/SLA.0000000000000966.
[23]	Lu SL, Hsu FM, Tsai CL, et al. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: hypojournal generating for adjuvant treatment[J]. Eur J Surg Oncol, 2019, 45(8):1498-1504. DOI: 10.1016/j.ejso.2019.03.020. doi: 10.1016/j.ejso.2019.03.020
[24]	Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG Oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation[J]. J Thorac Oncol, 2017, 12(2):368-374. DOI: 10.1016/j.jtho.2016.10.002. doi: 10.1016/j.jtho.2016.10.002
[25]	Ajani JA, Xiao L, Roth JA, et al. A phase Ⅱ randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer[J]. Ann Oncol, 2013, 24(11):2844-2849. DOI: 10.1093/annonc/mdt339. doi: 10.1093/annonc/mdt339 pmid: 23975663
[26]	Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study[J]. Cancer, 2013, 119(5):939-945. DOI: 10.1002/cncr.27822. doi: 10.1002/cncr.v119.5
[27]	Cohen C, Tessier W, Gronnier C, et al. Salvage surgery for esophageal cancer: how to improve outcomes?[J]. Ann Surg Oncol, 2018, 25(5):1277-1286. DOI: 10.1245/s10434-018-6365-1. doi: 10.1245/s10434-018-6365-1
[28]	Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19):5458-5468. DOI: 10.1158/0008-5472.can-14-1258. doi: 10.1158/0008-5472.CAN-14-1258 pmid: 25274032
[29]	Nataliya VU, James DM, Daniel MC, et al. Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer[J]. J Clin Oncol, 2019, 37(15_suppl):4041-4041. DOI: abs/10.1200/JCO.2019.37.15_suppl.4041 doi: 10.1200/JCO.2019.37.15_suppl.4041
[30]	Jiao R, Luo H, Xu W, et al. Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities[J]. Onco Targets Ther, 2019, 12:6023-6032. DOI: 10.2147/OTT.S214579. doi: 10.2147/OTT
[31]	van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. A phase Ⅱ feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: the PERFECT trial[J]. J Clin Oncol, 2019, 37(15_suppl):4045-4045. DOI: abs/10.1200/JCO.2019.37.15_suppl.4045. doi: 10.1200/JCO.2019.37.15_suppl.4045
[32]	Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial[J]. BMC Cancer, 2018, 18(1):142. DOI: 10.1186/s12885-018-4034-1. doi: 10.1186/s12885-018-4034-1 pmid: 29409469
[33]	Borggreve AS, Mook S, Verheij M, et al. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (pride): a multicenter observational study[J]. BMC Cancer, 2018, 18(1):1006. DOI: 10.1186/s12885-018-4892-6. doi: 10.1186/s12885-018-4892-6 pmid: 30342494
[34]	Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378):926-930. DOI: 10.1126/science.aar3247. doi: 10.1126/science.aar3247
[35]	Paterson AL, Lao-Sirieix P, O'Donovan M, et al. Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms[J]. Histopathology, 2017, 70(2):203-210. DOI: 10.1111/his.13039. doi: 10.1111/his.13039 pmid: 27417524